<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01766895</url>
  </required_header>
  <id_info>
    <org_study_id>KMUH-IRB-980083</org_study_id>
    <secondary_id>100CM-KMU-09</secondary_id>
    <nct_id>NCT01766895</nct_id>
  </id_info>
  <brief_title>Long-term Follow Up of Viral Hepatitis in Uremic Patients in Taiwan</brief_title>
  <official_title>Long-term Follow Up of Viral Hepatitis in Uremic Patients in Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Medical University Chung-Ho Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The linkage between viral hepatitis and renal failure is complex. The current study aims to&#xD;
      exlore the long-term prevalence of viral hepatitis among uremic patients in Taiwan&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are prospectively recruited from 15 hemodialysis units including one medical center,&#xD;
      3 satellite hospitals and 11 local clinics in Taiwan. Patients who provided informed consents&#xD;
      for blood tests including genetic study related to HCV spontaneous seroclearance are enrolled&#xD;
      for analysis. All the eligible subjects are tested for both HCV antibodies (third-generation,&#xD;
      enzyme immunoassay; Abbott Laboratories, North Chicago, IL) and hepatitis B surface antigen&#xD;
      (HBsAg). HCV RNA is tested by polymerase chain reaction (Cobas Amplicor Hepatitis C Virus&#xD;
      Test, V.2.0; Roche Diagnostics, Branchburg, New Jersey, USA; detection limit: 50 IU/ml) twice&#xD;
      for at least 6 months apart if anti-HCV is positive to ensure chronicity of HCV infection.&#xD;
      HBsAg is quantified with the use of a standard quantitative chemiluminescent microparticle&#xD;
      immunoassay (ARCHITECT HBsAg, Abbott Diagnostics). The concentration of HBsAg in the specimen&#xD;
      is determined using a previously generated Architect HBsAg calibration curve (range, 0.05-250&#xD;
      IU/mL). Samples with serum HBsAg titer &gt;250 IU/mL were diluted at 1:20 and 1:500 with the&#xD;
      Architect HBsAg diluent and retested to expand the upper limit of the dynamic range from 250&#xD;
      to 125,000 IU/mL. Serum HBV DNA is determined by a standardized automated quantitative PCR&#xD;
      assay (Cobas Amplicor HBV Monitor; Roche Diagnostics; detection limit 200 copies/ml) if&#xD;
      patients are seropositive for HBsAg.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 2011</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>seroprevalence of viral hepatitis in uremic patients</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>factors associated with HCV clearance or reappearance</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>HBV seroconversion</measure>
    <time_frame>10 years</time_frame>
    <description>Factors assocaited with HBV seroconversion</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Uremia</condition>
  <condition>Viral Hepatitis</condition>
  <arm_group>
    <arm_group_label>uremic patients</arm_group_label>
    <description>blood sampling of viral hepatitis in uremic patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sampling</intervention_name>
    <description>blood sampling of viral hepatitis to determined seroprevalence in uremic patients</description>
    <arm_group_label>uremic patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      host factors ssociated with viral hepatitis&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Uremic patients will recruited from 15 hemodialysis units including one medical center, 3&#xD;
        satellite hospitals and 11 local clinics in Taiwan.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  uremic patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Nil&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chung-Feng Huang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>886</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chung-Feng Huang, MD</last_name>
      <phone>88673121101</phone>
      <phone_ext>7475</phone_ext>
      <email>fengcheerup@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Chung-Feng Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ming-Lung Yu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 1, 2013</study_first_submitted>
  <study_first_submitted_qc>January 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2013</study_first_posted>
  <last_update_submitted>March 2, 2019</last_update_submitted>
  <last_update_submitted_qc>March 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uremia</keyword>
  <keyword>HBV</keyword>
  <keyword>HCV</keyword>
  <keyword>seroclearance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Uremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

